The company says the government’s offer dumps too much risk on the manufacturer, threatening access to one of the world’s most sought after diabetes and weight loss treatments.
Australia’s Pharmaceutical Benefits Scheme recently approved Mounjaro for public funding after knocking it back several times but tied that long awaited listing to strict conditions. Under the proposed arrangement, Eli Lilly would carry what it calls a disproportionate share of the financial risk for subsidised prescriptions.
The scheme is designed to cap taxpayer exposure if demand surges or treatment costs blow out. Eli Lilly’s international leadership argues the final deal on the table cannot work in its current form.
Behind the scenes, talks between the company and the Pharmaceutical Benefits Scheme continue, but both sides remain far apart on how to balance cost and access. The sticking point centres on how much budget risk the government can shift onto the drugmaker for a therapy likely to see strong and sustained use.
From Eli Lilly’s perspective, those risk sharing requirements undermine the commercial case for supplying Mounjaro at scale under subsidy. The firm is signalling it will not lock in a deal that could leave it exposed to open ended liabilities.
The standoff highlights growing tension between governments trying to contain drug budgets and pharmaceutical giants expecting returns on high value therapies. Australia’s tough stance on risk sharing for Mounjaro is shaping up as a test case for how it will handle other expensive metabolic and obesity drugs.
Drugmakers will be watching whether a compromise emerges that still makes national reimbursement worthwhile. For patients, the outcome may determine how quickly next generation treatments move from global headlines to local pharmacy shelves.
